🇺🇸 FDA
Pipeline program

avelumab

B9991040

Phase 2 small_molecule terminated

Quick answer

avelumab for Squamous Cell Carcinoma of the Head and Neck (SCCHN) is a Phase 2 program (small_molecule) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).

Program details

Company
NEKTAR THERAPEUTICS
Indication
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials